Anagrelide Capsules USP — Class I drug recall D-0992-2022
Terminated recall by Teva Pharmaceuticals USA Inc, reported 2022-06-08, distributed nationwide. Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.
| Recall number | D-0992-2022 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA Inc, Parsippany, NJ, United States |
| Recall initiated | 2022-05-11 |
| Classified | 2022-06-08 |
| Reported by FDA | 2022-06-08 |
| Terminated | 2024-02-26 |
| Distributed | Nationwide (US) |
| Quantity | 4,224 cartons |
| Reason classes | specification failure |
| NDC | 00172-5241-60 |
| Lot numbers | GD01090 |
| Expiration dates | 2022-05 |
Product
Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.
Reason for recall
Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0992-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.